Novartis Molecular Diagnostics (MDx), a unit within Novartis Pharma, is working to develop innovative companion diagnostics and other tests to inform physician decision-making regarding patient care and treatment. These tests aim to improve a physician’s ability to administer the right treatment, to the right patient, at the right time and at the right dose, thereby improving outcomes and potentially reducing healthcare spending.
Our vision is to become a world leader in molecular diagnostics and a trusted partner that is shaping the future of personalized medicine. Ultimately, we seek to transform the practice of medicine, and by so doing, to enhance the value we provide to patients, clinicians, payors, regulators, and society as a whole. For additional information on Novartis MDx, please visit our website.